OSE Immunotherapeutics
Nantes
About OSE Immunotherapeutics
OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $63.2M
- Funding stage: IPO
- Last round: Grant (May 2025)
- Ticker: epa:OSE
- Website: ose-immuno.com
- Phone: +33 014-329-7857
Industries & Categories
Biotechnology, Medical, Medical Device, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ose-immunotherapeutics-7854 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.